Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

Prognostic Factors of Oncological and Reproductive Outcomes in Fertility-Sparing Treatment of Complex Atypical Hyperplasia and Low-Grade Endometrial Cancer Using Oral Progestin in Chinese Patients

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Prognosis after fertility-sparing management with oralprogestin for women with complex endometrial hyperplasia and endometrial cancer

Oncologic and Reproductive Outcomes after Fertility‐sparing Management with Oral Progestin for Women with Complex Endometrial Hyperplasia and Endometrial Cancer

Outcome of Conservative Treatment and Subsequent Assisted Reproductive Technology for Patients with Early-Stage Endometrial Adenocarcinoma and Poor Fertility Potential

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

[Analysis of Prognosis and Pregnancy Outcomes of Fertility-Preserving Treatment for Patients with Stage Ⅰa, Grade 2 Endometrial Cancer].

Fertility-preserving Treatment Outcome in Endometrial Cancer or Atypical Hyperplasia Patients with Polycystic Ovary Syndrome.

[Clinical Analysis of Fertility-Sparing Therapy of Patients with Complex Atypical Hyperplasia and Endometrial Cancer].

Fertility Outcomes in Infertile Women with Complex Hyperplasia or Complex Atypical Hyperplasia Who Received Progestin Therapy and in Vitro Fertilization

EP657 the Risk Factors and Therapeutic Regimens Analyses in the Fertility-Sparing Treatment of Refractory Endometrial Atypical Hyperplasia and Endometrial Cancer

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity

Use of Clinicopathological Factors to Predict Prognosis of Fertility-Sparing Treatment for Endometrial Endometrioid Carcinoma and Atypical Hyperplasia

[Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles]

Efficacy and prognosis of fertility-preserved hysteroscopic surgery combined with progesterone in the treatment of complex endometrial hyperplasia and early endometrial carcinoma

Treatment Efficiency of Comprehensive Hysteroscopic Evaluation and Lesion Resection Combined with Progestin Therapy in Young Women with Endometrial Atypical Hyperplasia and Endometrial Cancer.

Analysis of Pregnancy-Associated Factors after Fertility-Sparing Therapy in Young Women with Early Stage Endometrial Cancer or Atypical Endometrial Hyperplasia

Clinicopathological Analysis Of Fertility-Sparing Treatment And Pregnancy Outcomes In Young Women With Early-Stage Endometrial Carcinoma

Oral Progestin Treatment for Early-Stage Endometrial Cancer: A Systematic Review and Meta-analysis.

Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin As a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma